T he poor prognosis of triple-negative breast cancer (TNBC), hallmarked by the absence of estrogen receptor (ER), progesterone receptor (PR) and HER2 expression, and its resistance to standard chemotherapies have considerably hindered overall survival rates for this disease 1, 2 . Immunotherapy, including programmed cell death protein-1 and programmed death ligand-1 (PD-1-PD-L1) blockade, has been demonstrated to inhibit cancer progression 3 . However, less than 20% of TNBC tissues are PD-L1 + , and the overall response rate of patients with PD-L1 + TNBC to blockage strategies ranges from 10% to 18.5% (ref. 4 ). These setbacks demand definition and genetic evidence of the molecular mechanisms of immunosuppression during tumor initiation.
One of the central roles of the immune system is the surveillance and elimination of malignant transformations 5 . To escape immunosurveillance, nascent malignant cells may develop diverse mechanisms, including reducing antigenicity so that antitumor lymphocytes fail to detect transformed cells, eliminating immunogenicity by upregulating immunoinhibitory molecules, and recruiting immunosuppressive cells to establish an immunosuppressive microenvironment 6, 7 . Mutation-derived tumor antigens, also known as neo-antigens, are produced through proteasome-mediated degradation, then transported into the endoplasmic reticulum, where the antigenic peptides are loaded onto the synthesized major histocompatibility complex class I (MHC class I) molecules and migrate to the cell surface to be recognized by cytotoxic T cells 8 . The presentation of neo-antigens derived from mutated proteins leads to tumor suppression 9 , indicating that mutation burden functions as a predictor of neo-antigens 9 and sensitivity to immunotherapy 10 . However, how tumor cells lose antigenicity is unknown, and therapeutic strategies that restore the antigen presentation pathway and sensitize cancers to immunotherapy are missing.
It has become increasingly apparent that many long noncoding RNAs (lncRNAs) are aberrantly expressed in a broad spectrum of cancers and play key roles in promoting and maintaining cancer characteristics 11, 12 . An increased understanding of lncRNAs should stimulate new directions for future research and therapeutic options that focus on lncRNAs as prognostic markers and therapeutic targets for human cancer 13 . Although our previous data have indicated that a lncRNA, LINK-A (long intergenic noncoding RNA for kinase activation), is involved in breast cancer drug resistance and hypoxia 14, 15 , genetic mouse models of lncRNAs with spontaneous tumor development remain elusive and are crucial for developing a proof of concept that lncRNAs function as oncogenes that drive tumor initiation.
Here we investigated the role of LINK-A using a transgenic (Tg) mouse model that represents human TNBC. LINK-A facilitated the association between phosphatidylinositol-(3,4,5)-trisphosphate (PtdIns(3,4,5)P 3 ) and inhibitory GCPRs, leading to reduced cyclic AMP (cAMP) concentrations and protein kinase A (PKA)-mediated phosphorylation of a E3 ligase, TRIM71. As a consequence, TRIM71 catalyzed the K48-linked polyubiquitination (poly-Ub) and proteasome-mediated degradation of Rb, p53 and peptide-loading complex (PLC) components, thereby contributing to decreased immunosurveillance.
Results

LINK-A correlates with immunosuppression.
We previously demonstrated that LINK-A is upregulated in TNBC compared with non-TNBC breast cancer tissues and is correlated with poor outcomes for patients with breast cancer. To investigate potential relationships between LINK-A and the immune microenvironment, we performed a TCGA (The Cancer Genome Atlas) pancancer analysis, finding that LINK-A is upregulated in multiple cancer types ( Supplementary Fig. 1a ). The expression of LINK-A was substantially correlated with relative immune cell abundance 16 (see Methods) and GZMB/CD8A messenger RNA expression ratio across multiple cancer types, and specifically anticorrelated with antigen-presenting cell (APC) and CD8 + T cell abundance in basallike breast cancer ( Fig. 1a and Supplementary Fig. 1b) . The top 25% of breast tumors with higher infiltration of activated CD8 + T cells and APCs exhibited substantially reduced LINK-A expression compared with the bottom 25% of breast tumors ( Supplementary  Fig. 1c ). Fluorescent multiplex (anti-PD-L1, CD3, CD8) immunohistochemistry staining and RNAscope indicated that human breast cancer tissues with high LINK-A expression exhibited low CD8 + CD3 + lymphocyte infiltration (Fig. 1b,c) . Thus, the expression of LINK-A is correlated with an immunosuppressive microenvironment.
To demonstrate the potential prognostic value of LINK-A in patients with TNBC who need immunotherapy, we determined the infiltration of CD8 + T cells in patients with TNBC who are receiving pembrolizumab (anti-PD-1) treatment. The patients with TNBC who responded to pembrolizumab exhibited relatively lower expression of LINK-A and higher CD8 + T cell infiltration compared with non-responders (Fig. 1d,e and Supplementary Fig. 1d ). CD8 + T cell infiltration in this cohort of patients with TNBC negatively correlated with LINK-A expression (Fig. 1f) .
The decreased APC infiltration in LINK-A-high TNBC suggested potentially impaired antigen presentation machinery, prompting an investigation into the status of the PLC components within the tumors. The protein levels of the PLC components, including TPSN, TAP1, TAP2 and CALR, were all downregulated in TNBC non-responders compared with responders upon pembrolizumab treatment (Fig. 1g) . Using modification-specific antibodies, we demonstrated that the K48-linked poly-Ub of TPSN (Lys537), TAP1 (Lys245), TAP2 (Lys213) and CALR (Lys48) was upregulated in non-responders, although the level of total polyubiquitinated proteins remained unaltered (Fig. 1g) , suggesting proteasome-regulated degradation of these components. Furthermore, the expression of LINK-A negatively correlated with the protein expression of TPSN, TAP1, TAP2 and CALR, as well as β 2 -microglobulin (β 2 M) and MHC class I in this cohort ( Fig. 1h and Supplementary  Fig. 1e-i ). These observations suggested the importance of LINK-A in modulating immune balance in favor of immunosuppression, and that the expression of LINK-A potentially modulates the protein levels of the PLC.
LINK-A drives basal-like breast cancer. Previous studies using mouse mammary tumor virus (MMTV) long terminal repeatdriven Neu (Erbb2), Ras and Myc Tg mice demonstrated the development of tumors in mouse mammary glands by 6-12 months [17] [18] [19] . Tg mice harboring a LINK-A-containing 'flox-stop-flox' cassette . The sample size for each cancer type is as follows: bladder urothelial carcinoma (BLCA; n = 252), breast invasive carcinoma (BRCA; n = 836), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC; n = 196), colon adenocarcinoma (COAD; n = 18), glioblastoma multiforme (GBM; n = 154), head and neck squamous cell carcinoma (HNSC; n = 426), kidney chromophobe (KICH; n = 66), kidney renal clear cell carcinoma (KIRC; n = 448), kidney renal papillary cell carcinoma (KIRP; n = 198), brain lower grade glioma (LGG; n = 486), liver hepatocellular carcinoma (LIHC; n = 200), lung adenocarcinoma (LUAD; n = 488), lung squamous cell carcinoma (LUSC; n = 220), ovarian serous cystadenocarcinoma (OV; n = 294), prostate adenocarcinoma (PRAD; n = 374), skin cutaneous melanoma (SKCM; n = 226), stomach adenocarcinoma (STAD; n = 284) and thyroid carcinoma (THCA; n = 496). The sample size for each BRCA subtype is as follows: basal (n = 139), Her2 (n = 67), LumA (n = 417) and LumB (n = 191). b, Fluorescent multiplex immunohistochemistry labeling using indicated antibodies (upper panel) or RNAscope (bottom panel) of human breast cancer tissues. Three independent experiments were performed and yielded similar results. Scale bars: 100 µm. c, Pearson correlation between relative LINK-A expression and CD8 staining intensity per visual field. Six fields per tissue were measured (n = 78 tissues). d, Fluorescent multiplex immunohistochemistry labeling using indicated antibodies of human TNBC tissues upon pembrolizumab treatment. Three independent experiments were performed and yielded similar results. Scale bars: 100 µm. e, Measurement of LINK-A RNA copy number (left) or GAPDH RNA copy number (right) of human TNBC tissues upon pembrolizumab treatment (n = 12 tissues) (not significant (NS), P = 0.925, **P = 0.0062). Results are mean ± s.d. P values were determined by unpaired two-tailed Student's t-test. f, Pearson correlation of CD8 staining intensity with the LINK-A copy number of human TNBC tissues upon pembrolizumab treatment (n = 12 tissues). g, Immunoblotting detection using indicated antibodies of human TNBC tissues upon pembrolizumab treatment. Three independent experiments were performed and yielded similar results. h, Pearson correlation of TAP1 immunoblotting intensities with the LINK-A copy number of human TNBC tissues upon pembrolizumab treatment (n = 12 tissues). IB, immunoblot.
were bred with MMTV-Cre mice to induce expression of LINK-A in mammary tissues (referred to as MMTV-Tg(LINK-A) mice) 20 ( Fig. 2a) . Two male founder Tg animals were generated ( Fig. 2a and Supplementary Fig. 1j ), and both founder animals passed the transgene to their offspring in accordance with Mendelian inheritance. All of the data reported are based on observations of the progeny of the two founder animals.
Moderate expression of LINK-A in mouse mammary glands following crossing with MMTV-cre was confirmed by RNA blot (Fig. 2b) . Virgin female mice with Tg expression of LINK-A developed mammary gland adenocarcinomas, which involve the entire epithelium of the gland (Fig. 2c) . Histologic evaluation indicated that at 8 weeks of age, the majority of mammary gland ducts appear normal (referred to as normal-like) (Fig. 2d) and 5 months old exhibited a reduced percentage of normal-like mammary gland ducts with a concurrently increased percentage of hypoplasia, ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) over the time, respectively (Fig. 2d,e) . The median time until development of hyperplasia, DCIS and IDC in virgin female MMTV-Tg(LINK-A) animals was 85, 136 and 161 d, respectively (Fig. 2f-h ). The primary mammary gland tumors metastasized to the lungs, which exhibited adenocarcinoma (Fig. 2i) . Of tumor-bearing MMTV-Tg(LINK-A) animals, lung metastasis developed in 88.7%, compared with no lung metastasis in the control MMTV-cre and Tg(LINK-A) animals ( Fig. 2j-l) . The copy number of LINK-A in MMTV-Tg(LINK-A) mouse tumors was comparable with that in human TNBC tissues (Supplementary  Table 1 and Supplementary Fig. 1k-m) . Immunohistochemistry indicated that MMTV-Tg(LINK-A) tumors exhibited similar expression of estrogen receptor-α, PR-A/B and HER2 as normal mammary glands ( Supplementary Fig. 2a,b) , suggesting that the MMTV-Tg(LINK-A) malignancies show no estrogen receptor, PR and HER2 amplification or upregulation.
We observed that MMTV-Tg(LINK-A) tumors harbored a similar number of missense somatic mutation burdens compared with human TNBCs (Supplementary Fig. 2c ). Furthermore, MMTVTg(LINK-A) tumors harbored non-silencing somatic mutations on Trp53 and Pik3ca genes that are frequently mutated in human TNBCs 21, 22 ( Supplementary Fig. 2d ). These observations suggested that the MMTV-Tg(LINK-A) tumors exhibit genetic similarity to human TNBCs, mimicking the bona fide tumor initiation and somatic mutation generation processes.
RNA-sequencing (RNA-seq) analyses of MMTV-Tg(LINK-A) tumors exhibited distinct transcriptional profiling compared with non-LINK-A-expressing Tg(LINK-A) mouse mammary glands ( Supplementary Fig. 2e ). The transcriptome of MMTV-Tg(LINK-A) tumors was coclustered with human basal-like breast cancers compared with other subtypes (Supplementary Fig. 2e) . Notably, upregulated genes in tumors versus normal tissues were enriched in cell-cycle and redox homeostasis, whereas downregulated genes were enriched in lipid metabolism, T cell activation and immunoresponse ( Supplementary Fig. 2f ).
Human TNBCs also exhibit a metabolic signature that is hallmarked by glycolysis and accumulation of redox 23 . Although the relative abundance of overall metabolites was comparable, MMTV-Tg(LINK-A) tumors were enriched with metabolites of glycolysis and redox homeostasis compared with normal tissues ( Supplementary Fig. 2g-i [24] [25] [26] (Table 1) . Upon expression of LINK-A, PtdIns(3,4,5)P 3 associated with G-protein-coupled receptors (GPCRs), which included cannabinoid receptor 2 (CNR2), γ-aminobutyric acid type B receptor subunit 1 (GABR1), α2A-adrenergic receptor (ADA2A), muscarinic acetylcholine receptor M4 (ACM4) and μ-type opioid receptor (OPRM) ( Table 1) . Upon ligand binding, GPCRs activated the associated G protein, in which the G-protein alpha subunit (Gα) can be classified as Gαs, Gαi, Gαq or G12/13 (ref. 27 ). Interestingly, CNR2, GABR1, ADA2A, ACM4 and OPRM all associate with Gαi, leading to inhibition of adenylyl cyclase and reduced cAMP production upon ligand binding 28 . Consistent with this notion, PtdIns(3,4,5)P 3 and Gαi exhibited robust interactions with GPCRs in MMTV-Tg(LINK-A) tumors compared with the mammary glands of Friend leukemia virus B (FVB) mice (background control mice) or MMTV-PyVT tumors (Fig.  3a) , despite similar PtdIns(3,4,5)P 3 enrichment ( Supplementary  Fig. 3a ). The presence of exogenous ligands may further facilitate these interactions.
To validate that the Gαi-GPCRs interaction is dependent on PtdIns(3,4,5)P 3 -bound LINK-A, we observed that fulllength LINK-A facilitated the interactions between glutathione S-transferase (GST)-tagged bacterially expressed human GPCRs and Gαi (Fig. 3b) . Conversely, the presence of a LINK-A PtdIns(3,4,5)P 3 binding motif deletion mutant (nucleotides 1081-1140) (referred to as ΔPIP 3 ) 15 failed to do so (Fig. 3b) . In LINK-A-low mouse/human mammary gland epithelial NMuMGMCF10A cells, exogenous expression of the full-length lncRNA, but not the ΔPIP 3 mutant, enhanced the recruitment of GPCRs to Gαi and PtdIns(3,4,5)P 3 ( Fig. 3c and Supplementary Fig. 3b ). In LINK-Ahigh MDA-MB-231 cells with a LINK-A PtdIns(3,4,5)P 3 -binding motif depletion (referred to as PIP 3 15 , reintroduction of full-length LINK-A, but not the mutant, rescued these interactions ( Supplementary Fig. 3c ).
Activation of Gαi results in reduced cellular cAMP concentration 28 . MCF10A-NMuMG cells harboring ∼100 copies of exogenous full-length LINK-A, but not the ΔPIP 3 mutant, showed considerably reduced cAMP concentrations and PKA phosphorylation at Thr197 (ref. 29 ) with minimally altered cellular PtdIns(3,4,5)P 3 ( Fig. 3d,e and Supplementary Fig. 3d-i) .
To determine the binding affinity of PtdIns(3,4,5)P 3 -GPCRs interactions, we applied an Alpha assay. This assay uses 'donor' and 'acceptor' beads to capture interacting biomolecules in proximity that leads to an energy transfer from one bead to the other, ultimately producing a luminescent/fluorescent signal. For these experiments, we used GST-tagged bacterially expressed GPCRs and biotinylated-PtdIns(3,4,5)P 3 as donor-acceptor pairs (Fig. 3f-h and Supplementary Fig. 3j,k) . Gαi exhibited non-detectable interactions with PtdIns(3,4,5)P 3 ; however, all five GPCRs showed moderate interactions with PtdIns(3,4,5)P 3 (K d 3.96-8.75 µM) and strong interactions with PtdIns(4,5)P 2 (K d 0.08-0.42 µM) (Fig. 3f,g and Supplementary Fig. 3j ). Next, we determined the K d value of PtdIns(3,4,5)P 3 -GPCRs interactions in the presence of LINK-A or a cardiolipin-binding lncRNA, RP11-383G10.5 (ref. 15 ), as a control ( Fig. 3h and Supplementary Fig. 3k ). In the presence of full-length LINK-A, but not the ΔPIP 3 PtdIns(3,4,5)P 3 -GPCRs interactions increased 15-to 18-fold compared with RP11-383G10.5 ( Fig. 3h and Supplementary Fig. 3k ).
The intracellular C termini of GPCRs harbor hydrophobic acyl groups that facilitate the recruitment of GPCRs to membrane lipid rafts 30 . We reasoned that the intracellular C termini of GPCRs are required for the crosstalk with LINK-A and PtdIns(3,4,5)P 3 . We used single-guide RNAs (sgRNAs) to deplete CNR2, GABR1, ADA2A, ACM4 or OPRM in the MDA-MB-231 cells (Fig. 3i-l and Supplementary Fig. 3l -q), followed by expression of wild-type or mutants with deletions in the C-terminal lipid raft binding domain (referred to as ΔCT), which had similar expression levels to endogenous GPCRs. Wild-type GPCRs, but not ΔCT mutants, rescued the PtdIns(3,4,5)P 3 -Gαi and GPCRs-Gαi interactions upon CNR2, GABR1, ADA2A, ACM4 or OPRM deletion (Fig. 3i,k and Supplementary Fig. 3l ,n,p). As a consequence, cellular cAMP levels were increased upon depletion of the GPCRs and were restored upon expression of wild-type GPCRs, but not the ΔCT mutants (Fig. 3j ,l and Supplementary Fig. 3m ,o,q). Expression of wild-type GPCRs or mutants showed minimal effect on cellular PtdIns(3,4,5) P 3 levels or the expression of LINK-A ( Supplementary Fig. 4a,b) . It is unlikely that the cell membrane expression of these GPCRs was affected upon ΔCT. Taken together, our data indicated that LINK-A, upon association with PtdIns(3,4,5)P 3 , facilitates PtdIns(3,4,5)P 3 -GPCRs and Gαi-GPCRs interactions, resulting in reduced intracellular concentrations of cAMP.
GPCR antagonist represses tumor cell proliferation. Our findings suggested that LINK-A-positive basal-like breast cancer may be addicted to GPCR signaling, which could be repressed with GPCRs antagonists or inhibitors. We screened and determined the effect of a cohort of GPCR antagonists/inhibitors using isolated tumor cells derived from MMTV-Tg(LINK-A) tumors (referred to as MMTV-LINK-A cells) and MDA-MB-231 (Fig. 4a) . Compared with the vehicle, the ADA2A antagonist rauwolscine exhibited potent effects on restoring cAMP concentrations in both MMTV-LINK-A and MDA-MB-231 cells (Fig. 4a ). Rauwolscine is a natural alkaloid that acts as a selective and reversible ADA2A antagonist (K i = 12 nM) 31 . The effect of rauwolscine on restoring the phosphorylation of PKA (Thr197) was validated in MMTV-LINK-A cells derived from individual MMTV-Tg(LINK-A) tumors, in which the protein expression of ADA2A or the PKA catalytic subunit was unaltered (Fig. 4b) .
Rauwolscine exhibited minor effects on the cell viability of MCF10A-NMuMG cells but robust cell cytotoxicity against MMTV-LINK-A and MDA-MB-231 tumor cells with half-maximal inhibitory concentration (IC 50 ) values of 30 and 40 nM, respectively ( Fig. 4c,d ). We then determined the efficacy of rauwolscine in modulating cell proliferation using a panel of TNBC and non-TNBC breast cancer cell lines, finding that treatment with rauwolscine specifically repressed the cell proliferation of TNBC cells, but not non-TNBC cells or normal cells (Fig. 4e,f) . Treatment with LINK-A locked nucleic acids (LNAs) showed similar repression of cell proliferation in TNBC cells, but not non-TNBC cells (Fig. 4g) . We then tested combinatorial strategies against the growth of MDA-MB-468 cells, which do not respond to current anti-epidermal growth factor receptor (EGFR) targeted therapies 32 . Individually, rauwolscine and the CDK4/CDK6 inhibitor abemaciclib, but not erlotinib, inhibited cell proliferation by 50%; however, a combined treatment consisting of rauwolscine with abemaciclib or erlotinib substantially repressed cell proliferation ( Supplementary Fig. 4c ). These findings suggested that inhibiting GPCR signaling may improve the sensitivity of TNBCs to anti-CDK4/CDK6 and anti-EGFR targeted treatments.
PKA stabilizes Rb and p53. We demonstrated that LINK-A activates GPCRs, leading to downregulation of cAMP and inactivation of PKA. Although PKA depletion leads to carcinogenesis 33, 34 , the underlying molecular mechanism of how PKA prevents tumor initiation is unknown. Using LC-MS as an open-ended technology, we identified PKA-binding proteins and the post-translational modifications of these proteins in MMTV-Cre mammary glands, MMTV-PyVT tumors 35 and MMTV-Tg(LINK-A) tumors (Table  2 and Supplementary Table 3 ). Whereas the catalytic and regulatory subunits of PKA were detected in all three types of tissues (Table 2) , PKA catalytic subunits (PKA-Cα, PKA-Cβ) exhibited phosphorylation at the Thr197 residues of both subunits in normal mammary glands and MMTV-PyVT tumors, but not in MMTV-Tg(LINK-A) tumors (Table 2) . Consistently, cAMP levels were reduced in MMTV-Tg(LINK-A) tumors compared with MMTV-cre mammary glands and MMTV-PyVT tumors (Fig. 5a ), validating the conclusion that expression of LINK-A inactivates the cAMP-PKA pathway.
PKA associated with TRIM71, an E3 ligase 36 , in all three types of tissues; however, in MMTV-Tg(LINK-A) tumors, PKA associated with the ubiquitin pathway components, RL40 (ubiquitin precursor), UBA1 (E1), UB3D2 (E2) and TRIM71 (E3) ( Table 2 ), suggesting that the ubiquitination pathway was activated in MMTVTg(LINK-A) tumors. Furthermore, TRIM71 was phosphorylated at Ser3 in normal tissues and MMTV-PyVT tumors, but not in MMTV-Tg(LINK-A) tumors (Table 2 and Fig. 5b,c) . These data suggested that TRIM71 is regulated by phosphorylation, and that hypophosphorylated TRIM71 associates with ubiquitin machinery. We then tested the hypothesis that the phosphorylation of TRIM71 at Ser3 is catalyzed by PKA, finding that CRISPR-mediated ablation of the genes encoding PKA catalytic subunits using sgRNAs reduced the phosphorylation of TRIM71. The expression of the wild-type PKA catalytic subunit, but not the kinase-dead mutant K72H (ref. 37 ), restored the phosphorylation of TRIM71 ( Supplementary  Fig. 4d,e) . In TNBC pembrolizumab treatment responders/nonresponders, the status of p-PKA-Cα (Thr197) and p-TRIM71 (Ser3) negatively correlated with LINK-A expression (Fig. 5d,e) . These observations suggested that LINK-A expression potentially inhibits PKA phosphorylation/activity and PKA-mediated phosphorylation of TRIM71 at Ser3.
Aiming to identify the ubiquitination substrates of LINK-A-PKA-TRIM71 signaling, we further analyzed our LC-MS data to 
A dash indicates that no proteins in the categories shown were pulled down with control or PIP 3 beads. identify the proteins with peptide adducts derived from ubiquitin. The C terminus of the mature ubiquitin has the amino acid sequence KESTLHLVLRLRGG, in which the last Gly can be conjugated to lysine residues on target proteins. When the conjugated ubiquitin is cleaved with trypsin, it leaves Gly-Gly (GG) residues on the modified lysine residues of the target proteins. Rb and p53 exhibited GG modifications at Lys803 and Lys126, respectively, which suggested ubiquitination modification of these proteins (Table 2 and Fig. 5f ). Ubiquitin contains seven lysine residues, K6, K11, K27, K29, K33, K48 and K63, through which a specific polyubiquitin chain can be formed upon a target protein.
To determine the types of polyUb chains on the target proteins in MMTV-Tg(LINK-A) tumors, we analyzed which lysine residues of ubiquitin are predominantly conjugated with the GG dipeptide, finding that lysine 48 of ubiquitin is largely modified by GG ( Supplementary Fig. 4f ). These data indicated that Ub-Rb and Ub-p53 are modified with K48-linked poly-Ub and are potentially subjected to proteasomal degradation 38 . Consistently, the protein status of Rb and p53, which have been shown to be downregulated in human breast tumors compared with normal adjacent tissues 39, 40 , were reduced in MMTV-Tg(LINK-A) tumors compared with mouse mammary glands (Fig. 5g-i) . Taken together, our data suggested that expression of LINK-A downregulates intrinsic tumor suppressor barriers via the GPCR-PKA-TRIM71 signaling axis during tumorigenesis. (Table 3 and Supplementary Table 4) , which have been shown to efficiently knockdown LINK-A in vivo 15 . Although the regulatory and catalytic subunits of PKA were detected under both conditions, the catalytic subunits exhibited phosphorylatedThr197 following LINK-A LNAs treatment (Table 3) . Furthermore, the LINK-A LNAs treatment restored the phosphorylation of TRIM71 (Ser3), with concurrent disassociation of ubiquitin, UBA1 and UB2D3 (Table 3 ). These observations suggested that the LINK-A LNAs treatment effectively reversed the inactivation of the cAMP-PKA pathway in MMTV-Tg(LINK-A) tumors.
LINK-A-dependent
In addition to Rb and p53, TRIM71 associated with all six components of the PLC, namely, TPSN, TAP1, TAP2, CALR, ERAP1 and PDIA3 in MMTV-Tg(LINK-A) tumors (Table 3) . The PLC components facilitate the folding and loading of antigenic peptides and the transportation of the MHC class I complex to the cellular surface 41 . TPSN, TAP1, TAP2 and CALR were all subjected to GG modification at the Lys213 (TPSN), Lys537 (TAP1), Lys245 (TAP2) and Lys48 (CALR) residues (Table 3) , and all ubiquitin that associated with TRIM71 or TRIM71-binding proteins was K48-linked ( Supplementary Fig. 4g ). Upon LINK-A LNAs treatment, the GG modifications at Lys213 (TPSN), Lys537 (TAP1), Lys245 (TAP2) and Lys48 (CALR) were all abolished (Table 3 and Supplementary  Fig. 4h ). These observations indicated that the TRIM71-associated PLC components were modified with K48-linked poly-Ub chains, which were diminished upon LINK-A knockdown. We developed modification-specific antibodies targeting Ub-TPSN (Lys213), Ub-TAP1 (Lys537), Ub-TAP2 (Lys245) and Ub-CALR (Lys48) (Supplementary Fig. 4i ).
To validate these observations, we observed that the protein levels of TPSN, TAP1, TAP2 and CALR were downregulated in MMTV-Tg(LINK-A) tumors, but not in MMTV-PyVT tumors or normal mammary gland tissues (Fig. 6a) . We further confirmed that in human breast cancer tissues (Duke cohort; Supplementary Table 1), the expression of LINK-A negatively correlated with the protein levels of TPSN and CALR (Supplementary Fig. 5a ). In TNBC resistant to anti-PD-1 blockage, Ub-TPSN, Ub-TAP1, Ub-TAP2 and Ub-CALR were all substantially increased compared with patients with anti-PD-1-sensitive TNBC (Supplementary Fig. 5b ).
To demonstrate that expression of LINK-A downregulates PLC components during tumor initiation, we took advantage of the mammary ductal transformation process of the normal-like, hyperplasic, DCIS and IDC morphologies of MMTV-Tg(LINK-A) mice. Compared with the normal ducts of Tg(LINK-A) mice (Fig. 6b, first  column) , although the ducts of MMTV-Tg(LINK-A) mouse mammary glands at 8 weeks of age were morphologically similar to normal ducts, the protein status of TPSN and CALR was considerably downregulated in the epithelial cells of these normal-like ducts (Fig.  6b, second column, and 6c) , suggesting that the PLC complex is likely to be downregulated in mammary gland epithelial cells without substantial lymphocyte infiltration or accelerated cell division. In hyperplasic ducts, the protein status of TPSN and CALR was 
A dash indicates that no proteins in the categories shown were pulled down with IgG or anti-PKA. further downregulated compared with normal-like ducts, whereas the atypical hyperplasic ducts, DCIS and IDCs all exhibited similar low-PLC status (Fig. 6b,c and Supplementary Fig. 5c,d ). Hence it is highly possible that one of the mechanisms by which malignant cells lose antigenicity during tumor initiation is through LINK-Adependent downregulation of antigen-presenting machinery.
Proteasome-mediated protein degradation occurs in the cytosol 42 ; it is highly likely that the translated MHC class I complex and PLC components are subject to proteasome-medicated protein degradation before the assembly on the endoplasmic reticulum membrane. We addressed the hypothesis that the expression of LINK-A facilities the interactions between TRIM71 and PLC components, which could be reduced upon LINK-A knockdown using Duolink proximity ligation assay (PLA) signals (Supplementary Fig. 5e ). Robust PLA signals were detected in MDA-MB-231 cells harboring Scr LNAs, suggesting protein proximity between TRIM71:TAP1, TRIM71:CALR, TRIM71:TAP2 and TRIM71:TPSN, respectively, which were substantially reduced ( Supplementary Fig. 5f ). The majority of PLA signals did not overlap with endoplasmic reticulum markers, suggesting that a portion of PLC components could be subjected to TRIM71-mediated poly-Ub and protein degradation on the exterior of the endoplasmic reticulum, which is consistent with previous literature suggesting that a portion of the MHC class I complex overlaps with the endoplasmic reticulum marker 43 . Tumor-bearing MMTV-Tg(LINK-A) mice treated with LINK-A LNAs showed restored phosphorylation of PKA (Thr197) and p-TRIM71 (Ser3), and elevated protein levels of TPSN, TAP1, TAP2 and CALR without affecting the total protein levels of PKA and TRIM71 (Fig. 6d and Supplementary Fig. 6a,b) . To determine the poly-Ub types of the Ub-TPSN, Ub-TAP1, Ub-TAP2 and Ub-CALR, we performed denaturing immunoprecipitation to immunoprecipitate similar amounts of TPSN, TAP1, TAP2 and CALR proteins in MMTV-Tg(LINK-A) tumors. Upon Scr LNAs treatment, the immunoprecipitated proteins exhibited K48-linked 
A dash indicates that no proteins in the categories shown were pulled down with IgG or anti-TRIM71. , subcutaneously, every other day). Five animals per experimental conditions were examined. Three independent experiments were performed and yielded similar results. e, Immunoblotting detection using indicated antibodies in lysates extracted from MMTV-Tg(LINK-A) tumors treated with vehicle or rauwolscine (10 mg kg poly-Ub chains, which were diminished upon LINK-A LNAs treatment ( Supplementary Fig. 6b ). Treatment with rauwolscine efficiently restored the protein levels of the PLC components, as well as inhibited the K48-linked poly-Ub of these proteins without affecting LINK-A expression in these tumors ( Fig. 6e and Supplementary  Fig. 6c,d) .
The PLC complex is vital for the stabilization and cellular presentation of the MHC class I complex. To determine the functional role of LINK-A and the TRIM71-dependent molecular mechanism in antigen presentation, we determined the cellular surface MHC class I complex of the B16F10 cells with Tet-on-induced expression of LINK-A, finding that expression of LINK-A suppressed the cellular surface expression of H-2K b with or without interferon-γ (IFN-γ) stimulation (Fig. 6f and Supplementary Fig. 7a) . Similarly, expression of exogenous TRIM71 led to reduced cell surface expression of H-2K b ( Supplementary Fig. 7b,c) . Furthermore, Trim71 knockdown blocked the LINK-A-dependent cellular surface suppression of H-2K b in B16F10 cells (Supplementary Fig. 7d ). Fig. 7h-j) . Treatment with rauwolscine considerably improved the cellular surface expression of MHC class I and β 2 M (Fig. 6g and Supplementary Fig. 7k ). Using B16-ovalbumin (OVA) cells 44 , we observed that knockdown of Trim71 increases cellular surface expression of the chicken OVA peptide (Fig. 6h) . Hence LINK-A downregulates PLC components and impairs antigen presentation, leading to tumor immunosurveillance evasion.
LINK-A LNAs suppress tumor initiation and progression.
Administration of LINK-A or rauwolscine exhibited minimal effects on the body weight, liver functions and renal functions of the mice (Supplementary Fig. 8a-f) . As a prevention trial, 12-weekold female MMTV-Tg(LINK-A) mice without palpable mammary gland tumors were treated with LINK-A LNAs or rauwolscine for a 16-week period. Mice given the vehicle treatment exhibited hyperplasia and atypical hyperplasia throughout their mammary glands with the presence of DCIS and IDCs (Fig. 7a,b) . The ducts of mice subjected to LINK-A LNAs or rauwolscine treatment exhibited a low degree of atypical hyperplasia and DCIS with more than 80% normal-like ducts (Fig. 7a,b) . The LINK-A LNA-or rauwolscinetreated mice also exhibited reduced tumor incidence (Fig. 7c,d) . LINK-A LNA-or rauwolscine-treated mammary glands exhibited restored protein statuses of CALR and TPSN in ductal epithelial cells and increased CD8
+ T cell infiltration compared with the vehicle-treated group (Fig. 7a,e,f) .
In our regression model, the tumor-bearing MMTV-Tg(LINK-A) mice treated with LINK-A LNAs exhibited inhibited tumor growth and reduced lung metastasis compared with those treated with Scr LNAs (Fig. 7g-i and Supplementary Fig. 8g ). The LINK-A LNAtreated tumors showed increased protein levels of CALR and TPSN (Fig. 7j,k) .
We then developed a syngeneic breast tumor model derived from MMTV-Tg(LINK-A) genetic mice using orthotopic transplantation of the mouse tumors to female FVB mammary glands. Treatment with LINK-A LNAs, rauwolscine or immune checkpoint blockers (ICBs) inhibited tumor growth in the syngeneic MMTVTg(LINK-A) tumors, which was synergistically suppressed by a combinatorial treatment of LINK-A LNAs/rauwolscine and ICBs (Fig. 8a,b) . The combined treatment substantially extended the survival time of the tumor-bearing mice (Fig. 8b) . We then determined the antitumor effect of small molecular inhibitors against CNR2, GABR1, ADA2A, ACM4 and OPRM using JTE907 (CNR2 inhibitor), CPG54626 (GABR1 inhibitor), rauwolscine (ADA2A inhibitor), tropicamide (ACM4 inhibitor) and cyprodime (OPRM inhibitor), respectively, finding that individual administration of these inhibitors substantially inhibited the growth of MMTVTg(LINK-A) syngeneic tumors ( Supplementary Fig. 8h) .
We then determined the status of tumor-resident CD8 + T cells in MMTV-Tg(LINK-A) tumors, finding that the LNAs treatment substantially improved CD8 + /CD3 + T cell infiltration and cytotoxicity but exhibited minimal effects on the expression of PD-L1 in these tumors (Fig. 8c-f and Supplementary Fig. 8i) . The LINK-A LNAs treatment showed minimal effects on the infiltration of CD8 + T cells, macrophages and myeloid-derived suppressor cells (MDSCs) in non-tumor-bearing mammary glands ( Supplementary Fig. 8j-o) . Taken together, we demonstrated a lncRNA-mediated molecular mechanism that modulates intrinsic tumor suppressors and antigen presentation in breast tumor initiation and progression (Supplementary Fig. 8p ). Therefore, LINK-A may serve as a valuable biomarker for predicting the outcome of patients with TNBC who require immunotherapy, and targeting LINK-A further sensitizes breast tumors to immune checkpoint inhibitors.
Discussion
The battle between the immune system and malignant cells is constantly evolving, and cancer cells develop a variety of mechanisms to escape immunoediting. Although genetic evidence has indicated that malignant cells with restored antigenicity are subject to antitumor immunity, whether cancer cells passively or actively downregulate antigenicity remains elusive. We demonstrated that during breast cancer initiation, the transformed mammary gland epithelial cells downregulate antigen presentation machinery upon expression of LINK-A, illustrating one of the initial and important mechanisms through which cancer cells escape from immune checkpoints. We reasoned that mammary gland epithelial cells expressing LINK-A may exhibit antigenicity loss, which contributes to the survival and expansion of malignant cells. The PLC plays vital roles in antigen presentation and transportation of MHC class I. Posttranslational modifications of PLC components in cancer cells may serve as an advantageous mechanism for downregulating antigenicity without losing achieved genomic mutations and mutation-derived growth advantages. Treatment with LINK-A LNAs or GPCR antagonists like rauwolscine in vivo substantially improved the protein stability of the PLC components and MHC class I complex, leading to sensitization of mammary gland tumors to immunotherapy. Most importantly, the enhanced CD8 + T cell infiltration was specific to tumor tissues; the LINK-A LNAs treatment did not affect the distribution of CD8 + T cells, macrophages, or MDSCs in normal mammary glands. Hence our results suggested promising therapeutic strategies for improving antigen presentation and the efficacy of immunotherapy, which could be synergistic with immune checkpoint inhibitors. Expression of LINK-A mediated the crosstalk between inhibitory GPCRs and PtdIns(3,4,5)P 3 , leading to inactivation of the cAMP/PKA pathway. The LINK-A-dependent suppression of PKAdependent phosphorylation of TRIM71 resulted in the K48-linked poly-Ub and protein degradation of the intrinsic tumor suppressors Rb and p53 and the components of PLC. TRIM71 has been shown to modulate p53 degradation 45 . It is likely that LINK-A/TRIM71-dependent p53 ubiquitination is independent of MDM2 (ref. 46 ), which is consistent with the notion that the major ubiquitination residues of p53 mediated by MDM2 are located within the tetramerization domain of p53 (Lys320, Lys321, Lys351, Lys357, Lys370, Lys372, Lys373) 47 , whereas LINK-A-dependent, TRIM71-mediated p53 poly-Ub occurs at Lys126, which is within the DNA-binding domain of p53. , subcutaneously, every other day, total of seven doses) (n = 10 and 10 animals (top); n = 11 and 11 animals (bottom); ****P < 0.0001). Results are mean ± s.d. P values were determined by unpaired two-tailed Student's t-test. Numbers in quadrants indicate percentage of cells. d-f, Representative images (d) and statistical analysis of CD8 (e) and granzyme B (GB) (f) of syngeneic MMTV-Tg(LINK-A) mice treated with LINK-A LNA, ICB alone or in combination (n = 7, 7, 7 and 7 animals). Scale bars: 100 µm (d). e,f, **P < 0.01, ***P < 0.001. Results are mean ± s.d. P values were determined by one-way ANOVA.
Despite the genome-wide identification of noncoding RNAs in human diseases, limited genetic evidence has demonstrated the biological importance of lncRNAs in cancer initiation and progression. Tissue-specific expression of LINK-A in mouse mammary glands led to mammary gland carcinogenesis, implicating it as an oncogene. Genome-wide analysis indicated that MMTV-Tg(LINK-A) tumors represent human TNBC genetically, transcriptionally and metabolically. Hence the MMTV-Tg(LINK-A) mouse model provides a valuable tool for studying the underlying molecular mechanisms of TNBC. The molecular mechanisms of LINK-A-driven breast tumors are mediated through multiple signaling pathways: we previously demonstrated that LINK-A expression mediates noncanonical HIF1α signaling and hyperactivation of the AKT pathway 14, 15 . With genetic evidence, our results suggested that LINK-A inactivates tumor suppressor pathways and downregulates antigen presentation through inactivation of PKA pathways, which is consistent with the previous notion that PKA knockout leads to carcinogenesis. Although the total protein level of TRIM71 exhibited minimal changes under our experimental conditions, phosphorylated TRIM71 faithfully correlated with the outcome of patients with TNBC treated with immunotherapy, suggesting that the LINK-A-PKA-TRIM71 signaling axis likewise correlates with patient outcomes. These results implicated the potential for these molecules to serve as biomarkers for predicting the outcome of patients with cancer treated with immune checkpoint inhibitors.
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Methods
In vivo murine models and treatment procedures. A Tg mouse model. In brief, the generated pBT378-PGK-L4StrL-LINK-A vector contains the transgene for ɸC31 integrase-mediated recombination. A mixture of the construct and ɸC31 integrase mRNA was microinjected into the pronucleus of each of 80 zygotes in the FVB genetic background using TARGATTT Technology, and the injected zygotes were implanted into four CD1 foster mice. Twenty-three mice were born from the microinjection. Successful integration from the founder mice was identified by PCR analyses of genomic DNA using primers targeting LINK-A. After screening, two male positive founders (Tg-LINK-A mice) were identified. All mice had an FVB genetic background. Tg-LINK-A mice were crossed with MMTV-cre mice (Tg(MMTV-cre)1Mam; The Jackson Laboratory) to produce mice with LINK-A transgene expression in the mammary glands. MMTV-Tg(LINK-A) and Tg(LINK-A) female mice were used as experimental and control mice, respectively. All of the mice genotyping primer sequences can be found in Supplementary Table 5 .
For the prevention treatment, MMTV-Tg(LINK-A) mice started the LINK-A LNAs (5 mg kg −1 (mg per kg body weight), subcutaneously (SubQ), every other day), or rauwolscine (5 mg kg −1 intraperitoneally (i.p.), daily) treatment from 12 weeks of age, and the treatment was terminated at 28 weeks of age. After treatment, mice mammary gland tissues were collected for morphology and immunohistochemistry analysis. For the regression treatment, MMTVTg(LINK-A) mice bearing mammary tumors up to 150 mm 3 were randomly assigned to treatment groups and injected with the following drugs: Scr LNAs or LINK-A LNAs (5 mg kg
, SubQ, every other day). Tumors were measured three times per week, and mice were euthanized once the ethical endpoint was reached (tumor volume of 1,500 mm 3 , as determined by measuring the minimum and maximum tumor diameters and using the following formula: [π(minimum diameter) 2 (maximum diameter)/6]). Mice mammary glands and lungs were collected for morphology and immunohistochemistry analysis.
For establishment of the syngeneic MMTV-Tg(LINK-A) model, MMTVTg(LINK-A) mice bearing mammary tumors up to 600 mm 3 were euthanized, and the tumors were excised. Tumors were dissociated as a single cell using the gentle MACS Dissociator (Miltenyi Biotec) with a mouse Tumor Dissociation kit (Miltenyi Biotec). A single-cell suspension was generated after filtration through a 70-μm cell strainer (BD Falcon). Single-cell suspensions were used for primary culture or transplant injection. Cells (40,000 per gland) were injected into the right inguinal fat pad of 4-week-old female FVB/N recipients. Three weeks after transplantation, when mammary tumors had reached a size of about 150 mm 3 , mice were randomly assigned to treatment groups and injected with combinations of the following drugs: Scr or LINK-A LNA (5 mg kg −1 , SubQ, every other day; QIAGEN), rauwolscine hydrochloride (5 mg kg −1 i.p., daily; Tocris), JTE 907 (5 mg kg −1 i.p., daily; Tocris), CGP 54626 hydrochloride (5 mg kg −1 i.p., daily; Tocris), tropicamide (5 mg kg −1 i.p., daily; Tocris), cyprodime hydrochloride (5 mg kg −1 i.p., daily; Tocris), and anti-PD-1 (clone RMP1-14; Bio X Cell) and anti-CTLA-4 (clone UC10-4F10-11; Bio X Cell) as ICBs 100 μg every 72 h, or an isotype control antibody (clone LTF-2; Bio X Cell) 200 μg every 72 h. Tumors were measured three times per week, and mice were euthanized once the ethical endpoint was reached. After treatment, mice tumors were collected for morphology, flow cytometry and immunohistochemistry analysis.
Tissue samples. TNBC tissues from patients who responded or did not respond to pembrolizumab (10 mg kg −1 , every 2 weeks, total of 3-4 months) were purchased from Boston Bioscource Inc. Fresh frozen breast carcinomas and their adjacent normal tissues were obtained from Duke University. The study protocol was approved by the Institutional Review Board of Duke University Health System. All tissue samples were collected in compliance with informed consent policy. Clinical information is summarized in Supplementary Table 1 .
Immunohistochemistry, immunofluorescence and Duolink PLA. For multiplex immunohistochemistry staining, formalin-fixed, paraffin-embedded (FFPE) human tissues cut at a thickness of 5 µm were prepared, and the staining was conducted using a PD-L1, CD3ε and CD8α Multiplex IHC Antibody Panel (65713; Cell Signaling Technology) according to vendor's instructions and imaged with a confocal microscope (Zeiss). Duolink PLAs were performed following the manufacturer's instructions (Sigma), using antibodies targeting TRIM71, TAP1, TAP2, CALR and TPSN. In brief, cells on round-cover glass slips were fixed in 4% PFA at 25 °C for 15 min after PBS washing. Cells were permeabilized in 0.5% Triton X-100 for 10 min and then treated in accordance with the Duolink assay kit instructions. Antibody information is summarized in Supplementary Table  6 . The confocal microscope (LSM700; Carl Zeiss) was used for image analysis. The number of PLA signals per cell was calculated. Immunofluorescence and immunohistochemistry were performed as previously described 48 . Antibody information is summarized in Supplementary Table 6 .
Cell lines, transfection, treatments and cellular assays. Human TNBC cell lines MDA-MB-231, MDA-MB-468, BT549 and HCC-1187; human HER2 + breast cancer cell lines BT474 and SK-BR-3; human estrogen receptor (ER) + breast cancer cell lines MCF7, T47D and ZR-75-1; human normal mammary gland epithelial cell line MCF10A; and mouse mammary gland epithelial cell line NMuMG were purchased from American Type Culture Collection. SUM-149 (human TNBC cell line), B16-OVA (mouse melanoma cell line, a gift from H. Patrick) and B16F10 (mouse melanoma cell line) were maintained using standard media and conditions, and the Characterized Cell Line Core Facility (MD Anderson Cancer Center). Lincode SMARTpool short interfering RNA targeting Trim71 (636931) was used in this study, and the LNAs targeting LINK-A and the scrambled sequence were designed and synthesized by Exiqon. Short interfering RNA, LNA and plasmid transfections were performed using DharmaFECT4 (Dharmacon) and Lipofectamine 3000 (Life Technologies), respectively. B16F10 was constructed to stably express LINK-A by selection with G418 (1,500 μg ml ). Single clones were obtained by serial dilution. LINK-A PtdIns(3,4,5)P 3 -binding motif-deficient cell lines were generated using the CRISPR-Cas9 genome editing system by the Gene Editing/Cellular Model Core Facility (MD Anderson Cancer Center). For pharmacologic inhibition, cells or tumor spheroids were treated with abemaciclib (500 nM; Selleckchem), erlotinib (10 µM; Selleckchem) and rauwolscine hydrochloride (10 µM; Tocris) for the indicated times and at the indicated concentrations. Spheroid growth and invasion of indicated cells were conducted using a Cultrex 3-D Spheroid Fluorometric Proliferation/Viability Assay kit (Trevigen) according to vendor's instruction. For IC 50 determination, a serial twofold dilution of the indicated compound starting at 0.4 mM to 0.05 nM was incubated with appropriated cells or spheroids, as indicated. IC 50 values were derived by a log (rauwolscine) versus response-variable slope (four parameters) model for a competitive inhibition curve using GraphPad Prism 7 software. Total cellular cAMP was quantified using a cAMP Assay Kit (Competitive ELISA; ab65355; Abcam) according to the manufacturer's protocol.
Plasmid construction, protein recombination and purification. Mammalian expression vectors for full-length LINK-A and the deletion mutant were constructed by subcloning the gene sequences into a pCDNA3.1(+) backbone and pInducer20 inducible lentiviral expression vector (Life Technologies). Mammalian expression of full-length TRIM71, PKA-Cα, CNR2, GABR1, ADA2A, ACM4, OPRM and mutant vectors was constructed by subcloning the corresponding gene sequences into the His-tagged expression vector (pcDNA-DEST40) using the Gateway system (Life Technologies). Bacteria expression of full-length CNR2, GABR1, ADA2A, ACM4, OPRM and mutant vectors was constructed by subcloning the corresponding gene sequences into the GST-tagged expression vector pGEX-5X-1. All single-point and deletion mutations were generated using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies). Recombinant proteins were expressed in the Escherichia coli strain BL21-CodonPlus (DE3)-RIPL (Agilent Technologies) and purified using the Protein Purification Kit (Clontech).
Immunoprecipitation and immunoblotting. Cells, human tumor samples, mouse normal mammary gland tissues and mouse breast tumor samples were homogenized in 1× RIPA buffer (EMD Millipore) supplemented with Protease/ Phosphatase Inhibitor Cocktail (Pierce, Thermo Scientific), panobinostat (Selleck Chemicals) and methylstat (Sigma-Aldrich). Lysates were cleared by centrifugation at 13,000g for 15 min at 4 °C. Supernatants were analyzed for immunoblotting or immunoprecipitation with the indicated antibodies, and the immunoprecipitated proteins were subjected to either immunoblotting or protein identification by MS. For the denaturing immunoprecipitation, tissues were lysed using TSD buffer (50 mM Tris-HCl, pH 7.5, 1% SDS, 5 mM DTT) boiled for 10 min. The cleared lysates were used for immunoprecipitation. The elutions were loaded on NuPAGE 4%-12% Bis-Tris Gel (GenScript) and then analyzed for immunoblotting with the indicated antibodies summarized in Supplementary Table 6 .
RNA biology assays. Total RNA isolation and quantitative PCR with reverse transcription were performed as previously described 49 . Total RNAs in mouse normal mammary glands and mouse breast cancer samples were analyzed for LINK-A and Actb expression using biotin-labeled LNA probes (Exiqon) according to the instructions for the NorthernMax Kit (Ambion). Detection of LINK-A expression using RNAScope probe (designed by Advanced Cell Diagnostics) and image quantification were performed as previously described using a RNAScope 2.5 High Definition Assay kit according to the manufacturer's instructions (Advanced Cell Diagnostics). For DNA fluorescence in situ hybridization (FISH), single-cell suspensions from freshly harvested Tg(LINK-A) mammary
